Alliancebernstein L.P. bought a new stake in Pulse Biosciences (NASDAQ:PLSE) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 10,500 shares of the company’s stock, valued at approximately $248,000. Alliancebernstein L.P. owned approximately 0.06% of Pulse Biosciences at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Brown Advisory Inc. purchased a new position in Pulse Biosciences in the 4th quarter valued at about $248,000. Bank of New York Mellon Corp lifted its holdings in Pulse Biosciences by 113.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 55,567 shares of the company’s stock valued at $1,034,000 after purchasing an additional 29,588 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Pulse Biosciences by 13.8% in the 3rd quarter. Wells Fargo & Company MN now owns 61,398 shares of the company’s stock valued at $1,143,000 after purchasing an additional 7,465 shares in the last quarter. Citadel Advisors LLC purchased a new position in Pulse Biosciences in the 4th quarter valued at about $7,975,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in Pulse Biosciences by 1,785.0% in the 4th quarter. The Manufacturers Life Insurance Company now owns 7,295 shares of the company’s stock valued at $172,000 after purchasing an additional 6,908 shares in the last quarter. Institutional investors own 10.84% of the company’s stock.
NASDAQ PLSE opened at $19.57 on Thursday. Pulse Biosciences has a 12 month low of $9.81 and a 12 month high of $39.50.
Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Friday, March 16th. The company reported ($0.53) EPS for the quarter.
A number of research analysts have issued reports on PLSE shares. BidaskClub lowered shares of Pulse Biosciences from a “hold” rating to a “sell” rating in a report on Friday, December 22nd. ValuEngine upgraded shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, December 31st.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/19/alliancebernstein-l-p-buys-shares-of-10500-pulse-biosciences-plse.html.
About Pulse Biosciences
Pulse Biosciences, Inc, a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications.
Want to see what other hedge funds are holding PLSE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pulse Biosciences (NASDAQ:PLSE).
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.